A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. (Q36892821)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 May 2013

Language	Label	Description	Also known as
English	A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.	scientific article published on 7 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pierfranco Conte

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Andrew M. Wardley

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Michelle E Melisko

8

object named as

Michelle Melisko

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

object named as

Hope S Rugo

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Mario Campone

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Dino Amadori

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Daniela Aldrighetti

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Cristian Villanueva

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Brent McHenry

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

David Liu

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francis Lee

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

0 references

publication date

7 May 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

139

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

411-419

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

copyright license

Creative Commons Attribution-NonCommercial 2.5 Generic

7 May 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

29 September 2017

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

27 June 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

4 September 2018

Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669514

4 September 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2552-8

21 January 2018

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2552-8

21 January 2018

The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-013-2552-8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23649189%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36892821&oldid=2199513100"